Ocugen Inc (OCGN) stock saw a decline, ending the day at $0.73 which represents a decrease of $-0.05 or -6.41% from the prior close of $0.78. The stock opened at $0.78 and touched a low of $0.71 ...

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering ...

EST Ocugen (OCGN) files to sell 57.54M shares of common stock for holdersInvest with Confidence: Follow TipRanks' Top Wall Street ...

On Friday, Ocugen Inc (OCGN) stock saw a modest uptick, ending the day at $0.78 which represents no change from the prior close of of $0.78. The stock opened at $0.79 and touched a low of $0.77 during ...

This was the stock's second consecutive day of gains.

The stock's fall snapped a two-day winning streak.

Ocugen (OCGN) announced that the U.S. FDA has reviewed the company’s Investigational New Drug application and it is in effect. This is a ...

OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in ...

Ocugen (NASDAQ:OCGN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at Chardan Capital in a research note issued to investors on Thursday,Benzinga reports.

Jan. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies ...

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410 ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...